This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
=== Suarez's third government and the "23-F" (1979–1981) === Once the Constitution was approved, Adolfo Suárez dissolved the Cortes and called new elections. The result did not satisfy either of the two major parties as things remained as they were in 1977. UCD won again but without reaching the absolute majority as it intended and the PSOE did not improve its results appreciably and remained in the opposition despite the fact that it had absorbed Tierno Galván's PSP. The same happened with AP, which ran under the name Democratic Coalition, and the PCE, which also failed to gain positions. A month after the general elections, the first municipal elections since the 2nd Republic took place, which this time resulted in the victory of the left, occupying the mayor's offices in most of the major cities thanks to the post-electoral pacts signed by the PSOE and the PCE. While the socialists Enrique Tierno Galván and Narcís Serra, occupied the mayoralties of Madrid and Barcelona, respectively, the communist Julio Anguita became the first communist mayor of a large Spanish city ─ Córdoba ─ of all its history.
== See also == List of cancer hospitals National Cancer Institute – U.S. health institute National Comprehensive Cancer Network – Non-profit organization in the U.S. Oncology – Branch of medicine dealing with, or specializing in, cancer
Poppy tea is a herbal tea infusion brewed from poppy straw or seeds of several species of poppy. The species most commonly used for this purpose is Papaver somniferum, which produces opium as a natural defense against predators. In the live flower, opium is released when the surface of the bulb, called the seed pod, is pierced or scraped. For the purpose of the tea, dried pods are more commonly used than the pods of the live flower. The walls of the dried pods contain opiate alkaloids, primarily consisting of morphine and codeine. The tea is consumed for its narcotic effect, and in small amounts for analgesic, anti-diarrheal, and sedative effects. It has also been known to be used as a method of relieving withdrawal symptoms. Use of such preparations originated in parts of Central and Eastern Europe, the Levant and Near East, and Central and South Central Asia millennia ago. The flowers of the poppy plant have long been used as a painkiller for soothing mild aches and pains (e.g. toothache, earache and sore throat), a mild sedative/relaxant, an expectorant for treating catarrh and coughs, as a digestive, and even for reducing the appearance of wrinkles and in lipsticks. This tea is depicted both in Asian literature, Western literature, and is depicted as being available in opium dens.
Sources: en.wikipedia.org
=== Respiration === Earthworms have no special respiratory organs. Gases are exchanged through the moist skin and capillaries, where the oxygen is picked up by the haemoglobin dissolved in the blood plasma and carbon dioxide is released.
Interestingly, relocalization of eIF4E from the nucleus to the cytoplasm correlated with clinical remissions indicative of the relevance of its nuclear activities to disease progression. Subsequent ribavirin trials in AML in combination with antileukemic drugs again showed objective clinical responses including remissions and molecular targeting of eIF4E. Clinical responses correlated with reduced nuclear eIF4E and clinical relapse with re-emergence of eIF4E nuclear eIF4E and its RNA export activity in these AML studies. Other studies used ribavirin in combination showed similar promising results in head and neck cancer. Ribavirin impairs all of the activities of eIF4E examined to date (splicing, capping, RNA export and translation). Thus, eIF4E has been successfully therapeutically targetable in humans; however drug resistance to ribavirin is an emergent problem to long term disease control. eIF4E has also been targeted by antisense oligonucleotides which were very potent in mouse models of prostate cancer, but in monotherapy trials in humans did not provide clinical benefit likely due to the inefficiency of reducing eIF4E levels in humans compared to mice. Recent improvements in nanoparticle delivery may improve this strategy. There is also an allosteric inhibitor of eIF4E which binds between the cap-binding site and the dorsal surface that is used experimentally.
== Further reading == Picknett, Lynn and Prince, Clive: The Turin Shroud: In Whose Image?, Harper-Collins, 1994 ISBN 0-552-14782-6. Antonacci, Mark : The Resurrection of the Shroud, M. Evans & Co., New York 2000, ISBN 0-87131-890-3 Whiting, Brendan, The Shroud Story, Harbour Publishing, 2006, ISBN 0-646-45725-X Di Lazzaro, Paolo (ed.) : Proceedings of the International Workshop on the Scientific Approach to the Acheiropoietos Images, ENEA, 2010, ISBN 978-88-8286-232-9. Olmi, Massimo, Indagine sulla croce di Cristo, Torino 2015 ISBN 978-88-6737-040-5 Jackson, John, The Shroud of Turin. A Critical Summary of Observations, Data, and Hypotheses, CMJ Marian Publishers, 2017, ISBN 9780692885734. Cozzo, Paolo; Merlotti, Andrea' Nicolotti, The Shroud at Court. History, Usages, Places and Images of a Dynastic Relic. Leiden-Boston: E.J. Brill, 2019.
The predictions of the effects of a major countervalue nuclear exchange include millions of city dweller deaths within a short period of time. Some 1980s predictions had gone further and argued that a full-scale nuclear war could eventually bring about human extinction. Such predictions, sometimes but not always based on total war with nuclear arsenals at Cold War highs, received contemporary criticism. On the other hand, some 1980s governmental predictions, such as FEMA's CRP-2B and NATO's Carte Blanche, have received criticism from groups such as the Federation of American Scientists for being overly optimistic. CRP-2B, for instance, predicted that 80% of Americans would survive a nuclear exchange with the Soviet Union, a figure that neglected nuclear war's impacts on healthcare infrastructure, the food supply, and the ecosystem and assumed that all major cities could be successfully evacuated within 3–5 days. A number of Cold War publications advocated preparations that could purportedly enable a large proportion of civilians to survive even a total nuclear war. Among these is Nuclear War Survival Skills. To avoid injury and death from a nuclear weapon's heat flash and blast effects, the two most common causes of injury from nuclear weapons, schoolchildren were taught to duck and cover by the early Cold War film of the same name. Such advice is once again being given in case of nuclear terrorist attacks.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.